Oncolytics Biotech Shares Rise on FDA Meeting Plan, Trial Progress in Colorectal Cancer
By Doc Louallen
Shares of Oncolytics Biotech rose after the company said it will hold an FDA meeting in August to discuss adding a registrational part to its ongoing randomized study in RAS-mutant, microsatellite-stable metastatic colorectal cancer, and reported operational progress in the trial.
Shares were recently up 16% at $1.03 late Monday morning. The stock is down 1.7% over the past three months.
Oncolytics said the meeting will cover adding Part B to REO-033, designed to support a potential accelerated approval and traditional approval within the same study.
The company said about half of the planned clinical sites will be activated this month, with more sites expected by the end of August. Also more than 20 patients have been pre-identified across participating centers.
Write to Doc Louallen at Doc.Louallen@wsj.com
(END) Dow Jones Newswires
July 13, 2026 10:59 ET (14:59 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
The Smartest Moves for Bond Investors Today, and What to Do When You Have Too Many Investments
Undervalued by 15%, This Utilities Stock Could Be an Unexpected AI Winner
5 Stocks to Sell for Tax-Loss Harvesting
33 Undervalued Stocks to Buy Before the Market Shifts Again
United States